Cancer drug olaparib tested for rare pancreatic tumor
NCT ID NCT05286827
First seen Apr 09, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare and aggressive pancreatic cancer. Only 5 participants were enrolled before the study was terminated. Participants took olaparib pills twice daily for up to 2 years. The goal was to see if the drug could shrink tumors or stop them from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ACINAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olaparib (Lynparza)
What this could lead to
If it works, this could point toward a treatment option for a rare and hard-to-treat pancreatic cancer.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The drug may not shrink tumors or improve survival, and side effects like fatigue or nausea are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.